Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Benzoic Acid Hydrazide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.56 |
| ▸ | MPO | P05164 | 2/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.56 |
| ▸ | KDM5A | P29375 | 1/20 | 0.56 |
| ▸ | BLM | P54132 | 1/20 | 0.56 |
| ▸ | GFER | P55789 | 1/20 | 0.56 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 7/20 | 0.55 |
| ▸ | CA1 | P00915 | 2/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.54 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.54 |
| ▸ | IDO1 | P14902 | 1/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 1/20 | 0.54 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.54 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Benzoic Acid Hydrazide SCHEMBL28917631 | 0.93 | CYP3A4 (0.58) | CYP3A4MPOGAAKDM5ABLM | |
| SCHEMBL20078583 | 0.93 | CYP3A4 (0.62) | CYP3A4MPOGAAKDM5ABLM | |
| Benzoic Acid Hydrazide SCHEMBL83514 | 0.93 | CYP3A4 (0.62) | CYP3A4MPOGAAKDM5ABLM | |
| Benzoic Acid Hydrazide SCHEMBL4515671 | 0.93 | CYP3A4 (0.62) | CYP3A4MPOGAAKDM5ABLM | |
| Benzoic Acid Hydrazide SCHEMBL1128823 | 0.91 | CYP3A4 (0.60) | CYP3A4MPOGAAKDM5ABLM | |
| Benzoic Acid Hydrazide SCHEMBL31087636 | 0.91 | CYP3A4 (0.60) | CYP3A4MPOGAAKDM5ABLM | |
| Benzoic Acid Hydrazide SCHEMBL922906 | 0.91 | CYP3A4 (0.60) | CYP3A4MPOGAAKDM5ABLM | |
| Benzoic Acid Hydrazide SCHEMBL31491462 | 0.91 | CYP3A4 (0.60) | CYP3A4MPOGAAKDM5ABLM | |
| Benzoic Acid Hydrazide SCHEMBL490987 | 0.91 | CYP3A4 (0.60) | CYP3A4MPOGAAKDM5ABLM | |
| Benzoic Acid Hydrazide SCHEMBL6469726 | 0.91 | CYP3A4 (0.60) | CYP3A4MPOGAAKDM5ABLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7759372-B2 | Nitrogen-containing heteroaryl compounds having inhibitory activity against HIV integrase | SHIONOGI & CO., LTD. (JP) | 2010-07-20 | — | — | US | disclosed |
| EP-2033952-A1 | Nitrogen-containing Heteroaryl compounds having HIV Integrase Inhibitory Activity | Shionogi&Co., Ltd. (JP) | 2009-03-11 | — | — | EP | disclosed |
| EP-1375486-B1 | NITROGEN-CONTAINING HETEROARYL COMPOUNDS HAVING HIV INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO (JP) | 2008-10-15 | — | — | EP | disclosed |
| US-20060293334-A1 | Nitrogen-containing heteroaryl compounds having inhibitory activity against HIV integrase | FUJI MASAHIRO | 2006-12-28 | — | — | US | disclosed |
| US-7148237-B2 | Nitrogen-containing heteroaryl compounds having HIV integrase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2006-12-12 | — | — | US | disclosed |
| US-20040127708-A1 | Nitrogen-containing heteroaryl compounds having hiv integrase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2004-07-01 | — | — | US | disclosed |
| EP-1375486-A1 | NITROGEN-CONTAINING HETEROARYL COMPOUNDS HAVING HIV INTEGRASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2004-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060293334-A1 | Nitrogen-containing heteroaryl compounds having inhibitory activity against HIV integrase | ZC3HAV1, INTS9, PRDM9 | CYP3A4 75/4885MPO 1144/4885GAA 2376/4885 |
| US-20040127708-A1 | Nitrogen-containing heteroaryl compounds having hiv integrase inhibitory activity | DUT, PNP, INMT | CYP3A4 118/4885MPO 1778/4885GAA 2274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.